Hospital
Smyth County Community Hospital
Smyth County Community Hospital was paid $15.33M by Medicaid between Jan 2018 and Dec 2024, across 201 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoSMYTH COUNTY COMMUNITY HOSPITAL
MARION, VA 24354
MARION, VA 24354
33aNPI1073519377assigned 06/22/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.33M
24GClaims478,081
24DCodes billed201
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#39 of 80
Median peer was paid$14.69M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HILTON, SHANE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 57,342 | $1.10M | |
| 2019 | 76,330 | $1.83M | |
| 2020 | 62,018 | $1.91M | |
| 2021 | 71,882 | $2.37M | |
| 2022 | 76,173 | $2.70M | |
| 2023 | 78,895 | $3.05M | |
| 2024incomplete | 55,441 | $2.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 24,028 | 20,437 | $3.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 17,108 | 14,793 | $2.09M |
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 9,149 | 7,142 | $1.77M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 11,094 | 9,375 | $1.22M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 3,323 | 2,975 | $574K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.7% | 12,359 | 3,680 | $567K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.6% | 4,237 | 3,766 | $548K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 3,260 | 2,797 | $468K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.7% | 7,835 | 7,041 | $421K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.6% | 2,309 | 2,069 | $393K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 5,042 | 4,340 | $268K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.6% | 2,513 | 791 | $238K |
189 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 904 | $234K |
| 80053 | Comprehensive metabolic panel | 1.3% | 32,722 | $199K |
| 36415 | Collection of venous blood by venipuncture | 1.3% | 21,214 | $194K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 2,118 | $188K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 2,540 | $183K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.2% | 1,164 | $182K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 2,747 | $154K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,156 | $120K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,102 | $107K |
| 97162 | <1% | 1,232 | $91K | |
| G0378 | Hospital observation service, per hour | <1% | 834 | $91K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 588 | $87K |
| 97113 | <1% | 1,438 | $68K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,925 | $67K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,576 | $67K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,594 | $62K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 576 | $50K |
| 81001 | <1% | 10,486 | $49K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,428 | $46K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,366 | $43K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,140 | $42K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 213 | $41K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,431 | $37K |
| 73130 | <1% | 1,562 | $35K | |
| 73610 | <1% | 1,511 | $34K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 223 | $33K |
| 72100 | <1% | 1,444 | $32K | |
| 73630 | <1% | 1,814 | $32K | |
| 83880 | <1% | 2,823 | $31K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,994 | $29K |
| 73562 | <1% | 1,683 | $28K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,982 | $27K |
| 81025 | <1% | 3,800 | $26K | |
| 97014 | <1% | 1,132 | $25K | |
| 73030 | <1% | 1,089 | $24K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 72 | $23K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,317 | $23K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,384 | $22K |
| 87040 | <1% | 4,670 | $21K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 165 | $21K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 111 | $21K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,602 | $20K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 190 | $20K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 870 | $20K |
| J3490 | Unclassified drugs | <1% | 1,439 | $20K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 911 | $19K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,082 | $17K |
| 73110 | <1% | 808 | $17K | |
| 80061 | Lipid panel | <1% | 4,587 | $17K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 915 | $16K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,803 | $16K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,381 | $15K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,083 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,990 | $14K |
| 97035 | <1% | 406 | $14K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,551 | $14K |
| 82607 | <1% | 3,454 | $13K | |
| 84484 | <1% | 9,300 | $13K | |
| 81003 | <1% | 6,579 | $13K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 65 | $12K |
| 93971 | <1% | 150 | $12K | |
| 80329 | <1% | 1,634 | $12K | |
| 74018 | <1% | 730 | $11K | |
| 87077 | <1% | 3,220 | $11K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 377 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,949 | $11K |
| 90715 | <1% | 676 | $10K | |
| 76830 | Ultrasound, transvaginal | <1% | 85 | $10K |
| 84439 | <1% | 1,873 | $9K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 288 | $8K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 448 | $7K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 852 | $7K |
| 73502 | <1% | 545 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,283 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,648 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,752 | $7K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 674 | $6K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 14 | $6K |
| 80143 | <1% | 1,137 | $6K | |
| 83605 | <1% | 3,750 | $5K | |
| 73221 | <1% | 28 | $5K | |
| 80320 | <1% | 1,075 | $5K | |
| 12001 | <1% | 25 | $5K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 129 | $5K |
| 71250 | <1% | 84 | $4K | |
| 85027 | <1% | 3,744 | $4K | |
| 82140 | <1% | 1,874 | $4K | |
| 87070 | <1% | 612 | $4K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 80 | $4K |
| 82728 | <1% | 1,211 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 628 | $3K |
| 87088 | <1% | 1,914 | $3K | |
| 71101 | <1% | 134 | $3K | |
| 87186 | <1% | 2,313 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 16 | $3K |
| 83540 | <1% | 2,322 | $3K | |
| 85379 | <1% | 854 | $3K | |
| 83735 | <1% | 4,453 | $3K | |
| 86140 | <1% | 823 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 20 | $3K |
| 82746 | <1% | 690 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 840 | $2K |
| 72040 | <1% | 87 | $2K | |
| 80179 | <1% | 1,125 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 86 | $2K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 18 | $2K |
| 83690 | <1% | 8,057 | $2K | |
| 85610 | <1% | 1,793 | $2K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 47 | $2K |
| 85652 | <1% | 1,135 | $2K | |
| 73080 | <1% | 89 | $1K | |
| 83550 | <1% | 616 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 205 | $1K |
| 87081 | <1% | 1,079 | $1K | |
| 84703 | <1% | 2,425 | $1K | |
| 96376 | <1% | 2,179 | $1K | |
| 94729 | <1% | 26 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,283 | $1K |
| 93017 | <1% | 26 | $836.59 | |
| 96523 | <1% | 17 | $804.36 | |
| 36600 | <1% | 185 | $716.76 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,753 | $708.51 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,212 | $682.13 |
| 84100 | <1% | 1,098 | $660.82 | |
| 96367 | <1% | 17 | $609.70 | |
| 83615 | <1% | 1,097 | $609.29 | |
| 87807 | <1% | 275 | $561.44 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,260 | $475.81 |
| 84466 | <1% | 352 | $440.00 | |
| 87205 | <1% | 367 | $372.99 | |
| 72072 | <1% | 14 | $361.17 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,143 | $354.92 |
| 80164 | <1% | 114 | $350.57 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,219 | $319.79 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 910 | $297.84 |
| 94727 | <1% | 12 | $245.37 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,940 | $239.06 |
| 86141 | <1% | 31 | $228.17 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,042 | $212.40 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 950 | $202.94 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 72 | $182.67 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 859 | $172.19 |
| 85730 | <1% | 179 | $144.83 | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 16 | $128.43 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $121.26 |
| 73090 | <1% | 12 | $118.65 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 468 | $114.09 |
| 83970 | <1% | 14 | $108.35 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 45 | $97.01 |
| 87147 | <1% | 74 | $95.82 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,470 | $74.39 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,169 | $66.98 |
| 86850 | <1% | 49 | $66.17 | |
| 87210 | <1% | 29 | $62.70 | |
| 82803 | <1% | 355 | $62.07 | |
| 84702 | <1% | 13 | $54.48 | |
| 82550 | <1% | 148 | $52.13 | |
| 88312 | <1% | 89 | $45.78 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 156 | $44.52 |
| 82272 | <1% | 28 | $37.73 | |
| 80050 | General health panel | <1% | 12 | $35.22 |
| 86900 | <1% | 70 | $35.21 | |
| 86901 | <1% | 66 | $31.73 | |
| 94760 | <1% | 323 | $29.24 | |
| 82565 | <1% | 30 | $23.48 | |
| 82150 | <1% | 26 | $21.64 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 282 | $17.26 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 332 | $14.03 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 12 | $13.00 |
| J1815 | Injection, insulin, per 5 units | <1% | 139 | $6.86 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 170 | $4.69 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 14 | $3.71 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 37 | $2.48 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,878 | $2.44 |
| 84550 | <1% | 13 | $2.41 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 64 | $2.18 |
| 99153 | Mod sedat endo service >5yrs | <1% | 14 | $1.19 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 95 | $0.72 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 32 | $0.23 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 14 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 36 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 17 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 21 | $0.00 |
| A9270 | Non-covered item or service | 0% | 31 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 22 | $0.00 |
| 94761 | 0% | 93 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 14 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 40 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 146 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHILTON, SHANE (EVP/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.